Current Clinical Trials
A first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is currently enrolling patients.
Completed Clinical Trials
The First-in-Human Phase 1 study of SBP-101 in patients with pancreatic ductal adenocarcinoma has reached completion in Australia and the United States.
Click here for summary of study results.